Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Neuroscience Research Australia | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to gather information about the effectiveness of abdominal FES to improve bowel management time (BMT) for people with chronic SCI. This study will also evaluate whether abdominal FES can improve: 1) bowel-related quality of life, 2) participant-reported bowel function, 3) bowel management strategy, 4) bladder symptoms, and 5) unplanned hospital admissions. In addition, we will also explore participant perspectives and experiences about the stimulation sessions and use of the device.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Abdominal Functional Electrical Stimulation | Experimental | All participants enrolled will receive the intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Abdominal Functional Electrical Stimulation | Behavioral | Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time. |
| Measure | Description | Time Frame |
|---|---|---|
| Bowel Management Time (BMT) | This is measured by recording start and end time of bowel management session in study diary. | Daily (Weeks 1-10) |
| Measure | Description | Time Frame |
|---|---|---|
| Bowel Management Strategy | This will be measured via analysis of daily diary entries regarding bowel movements (time taken and frequency), dietary changes or inconsistencies, and use of laxatives and manual procedures. The bowel diary will be completed daily throughout the study by participants and/or their caregivers. | Daily (Weeks 1-10) |
Not provided
Inclusion Criteria:
Chronic SCI (> 12 months since injury) above the level of T11
> 18 years of age
a measurable and consistent start and end event is determinable for the bowel routine
Portable smart device with video capabilities and internet access
Willingness to access and/or download Zoom (videoconferencing software)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Candy Tefertiller | Contact | 303-789-8000 | ctefertiller@craighospital.org | |
| Bria Mellick | Contact | 303-789-8757 | bmellick@craighospital.org |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Craig Hospital | Recruiting | Englewood | Colorado | 80113 | United States |
Not provided
| ID | Term |
|---|---|
| D013119 | Spinal Cord Injuries |
| D055496 | Neurogenic Bowel |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D020196 | Trauma, Nervous System |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Stimulation Dose |
This will be recorded by the participant. Participants will be asked to record the total time of active stimulation as displayed by the stimulation counter/timer and the intensity of the stimulation (milliamps) for each BM session in their bowel diary. The stimulation device will also record number of times the device button is depressed and duration in seconds, which can be downloaded at a later date by the research team providing further detail on stimulation dose. |
| During active stimulation period (Weeks 3-7) |
| EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Questionnaire | Quality of Life measure | Week 1, Week 3, Week 7, Week 10 |
| International Spinal Cord Society's (ISCoS) International SCI Bowel Function Basic Data Set Questionnaire | This instrument measures participant-reported bowel function bowel function. | Week 1, Week 3, Week 7, Week 10 |
| Visual Analog Scale (VAS) | This instrument measures participant perceptions of bowel function satisfaction on a rating scale from 0-100. | Week 1, Week 3, Week 7, Week 10 |
| Neurogenic Bladder Symptom Score (NBSS) | This instrument measures neurogenic bladder symptoms | Week 1, Week 3, Week 7, Week 10 |
| Intervention Acceptability | Qualitative and quantitative analysis of abdominal functional stimulation (AFES) use will be measured at the end of the active trial period, using both open-ended and 10-scored theoretical framework of acceptability questions to gain the perspective of people with lived experience of SCI on the use of AFES during a bowel routine | Week 7 |
| Intervention Safety | This will be determined by the reporting and summarization of any adverse events associated with the interventions. Participants will be instructed to record any adverse events in their bowel diaries and to call study staff immediately to review. Unplanned hospital visits will also be recorded in the study diary. | Daily (Weeks 0-10) |
| D014947 | Wounds and Injuries |
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |